Mahmoud Reza Jaafari1,2, Seyed Amir Jalali3, Reza Alimohammadi3, Razieh Alibeigi4, Amin Reza Nikpoor5, Ghanbar Mahmoodi Chalbatani6, Thomas J Webster7. 1. Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Department of Immunology, School of Medicine, Mashhad University of Medical Sciences, Tehran, Iran. 5. Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. 6. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 7. Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
Abstract
INTRODUCTION: Today, a new paradigm has emerged for cancer treatment introducing combination therapies. Doxil, a liposomal doxorubicin serving as a chemotherapeutic agent, is an effective immunogenic killer of cancer cells. Anti-CTLA-4 has been approved for the treatment of some cancers, including melanoma, but side effects have limited its therapeutic potential. METHODS: In this study, two approaches were utilized to increase treatment efficiency and decrease the side effects of anti-CTLA-4, combining it with chemotherapy and encapsulation in a PEGylated liposome. A different sequence of anti-CTLA-4 and Doxil was assessed in combination therapy using non-liposomal and liposomal anti-CTLA-4. RESULTS: Our results showed that liposomal anti-CTLA-4 reduced the size of established tumors and increased survival in comparison with non-liposomal anti-CTLA-4 in a well-established B16 mouse melanoma model. In combination therapy with Doxil, only the administration of anti-CTLA-4 before Doxil showed synergism in both non-liposomal and liposomal form and increased the CD8+/regulatory T cell ratio. DISCUSSION: In summary, our results demonstrate the potential of utilizing a nanocarrier system for the delivery of checkpoint blockers, such as anti-CTLA-4 which further showed potential in a combination therapy, especially when administered before chemotherapy.
INTRODUCTION: Today, a new paradigm has emerged for cancer treatment introducing combination therapies. Doxil, a liposomal doxorubicin serving as a chemotherapeutic agent, is an effective immunogenic killer of cancer cells. Anti-CTLA-4 has been approved for the treatment of some cancers, including melanoma, but side effects have limited its therapeutic potential. METHODS: In this study, two approaches were utilized to increase treatment efficiency and decrease the side effects of anti-CTLA-4, combining it with chemotherapy and encapsulation in a PEGylated liposome. A different sequence of anti-CTLA-4 and Doxil was assessed in combination therapy using non-liposomal and liposomal anti-CTLA-4. RESULTS: Our results showed that liposomal anti-CTLA-4 reduced the size of established tumors and increased survival in comparison with non-liposomal anti-CTLA-4 in a well-established B16 mouse melanoma model. In combination therapy with Doxil, only the administration of anti-CTLA-4 before Doxil showed synergism in both non-liposomal and liposomal form and increased the CD8+/regulatory T cell ratio. DISCUSSION: In summary, our results demonstrate the potential of utilizing a nanocarrier system for the delivery of checkpoint blockers, such as anti-CTLA-4 which further showed potential in a combination therapy, especially when administered before chemotherapy.
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Rafael Winograd; Katelyn T Byrne; Rebecca A Evans; Pamela M Odorizzi; Anders R L Meyer; David L Bajor; Cynthia Clendenin; Ben Z Stanger; Emma E Furth; E John Wherry; Robert H Vonderheide Journal: Cancer Immunol Res Date: 2015-02-12 Impact factor: 11.151
Authors: T Yamazaki; D Hannani; V Poirier-Colame; S Ladoire; C Locher; A Sistigu; N Prada; S Adjemian; J P P Catani; M Freudenberg; C Galanos; F André; G Kroemer; L Zitvogel Journal: Cell Death Differ Date: 2013-06-28 Impact factor: 15.828
Authors: R P Sutmuller; L M van Duivenvoorde; A van Elsas; T N Schumacher; M E Wildenberg; J P Allison; R E Toes; R Offringa; C J Melief Journal: J Exp Med Date: 2001-09-17 Impact factor: 14.307
Authors: Karla Parra; Paloma Valenzuela; Natzidielly Lerma; Alejandra Gallegos; Luis C Reza; Georgialina Rodriguez; Urban Emmenegger; Teresa Di Desidero; Guido Bocci; Mitchell S Felder; Marian Manciu; Robert A Kirken; Giulio Francia Journal: Br J Cancer Date: 2017-01-05 Impact factor: 7.640
Authors: Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke Journal: BMC Med Date: 2015-09-04 Impact factor: 8.775